Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation

Leuk Lymphoma. 2016;57(1):193-5. doi: 10.3109/10428194.2015.1036259. Epub 2015 Jun 18.

Authors

William Shomali¹, Cheryl Redmond², Samjhana Bogati², Cassandra Zimmerman², Valeria Visconte³, Ali Tabarroki³, Matt Kalaycio², Ramon V Tiu^{2

3}

Affiliations

¹ a Department of Internal Medicine , Cleveland Clinic , Cleveland , OH , USA.
² b Department of Hematologic Oncology and Blood Disorders , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.
³ c Department of Translational Hematology and Oncology Research , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.

PMID: 25942382
DOI: 10.3109/10428194.2015.1036259

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anticoagulants / therapeutic use*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Disease Progression
Humans
Imidazoles / administration & dosage
Imidazoles / adverse effects
Imidazoles / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Pyridazines / administration & dosage
Pyridazines / adverse effects
Pyridazines / therapeutic use*
Treatment Outcome
Venous Thromboembolism / diagnosis
Venous Thromboembolism / drug therapy*
Venous Thromboembolism / etiology*

Substances

Anticoagulants
Antineoplastic Agents
Imidazoles
Protein Kinase Inhibitors
Pyridazines
ponatinib